Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

A Framework for MRI Characterization of Intracranial Metastatic Disease.

Radiology. Imaging cancer·2026
Same author

Mitochondrial impairment and mTORC1 signalling exhaustion define NK Cell dysfunction progression in melanoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

European journal of cancer (Oxford, England : 1990)·2025
Same author

CP-GEP identifies high-risk T1a melanoma patients beyond established adverse features.

Journal of the American Academy of Dermatology·2025
Same author

Next-Generation Oncolytic Viruses to Overcome Resistance to Anti-PD-1 Therapy in Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: May 23, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Targeting NRAS in melanoma.

Fergal C Kelleher1, Grant A McArthur

  • 1Division of Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia.

Cancer Journal (Sudbury, Mass.)
|March 29, 2012
PubMed
Summary

NRAS mutations in melanoma are linked to thicker tumors and faster growth. Targeting NRAS offers a promising therapeutic strategy for this aggressive cancer, with new clinical trials exploring combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Cutaneous melanomas frequently harbor NRAS GTPase mutations (15% of cases).
  • NRAS-mutant melanomas exhibit increased tumor thickness and mitotic rate compared to BRAF-mutant or wild-type melanomas.
  • NRAS is crucial for melanoma cell survival and proliferation, presenting it as a key therapeutic target.

Purpose of the Study:

  • To review the therapeutic landscape for NRAS-mutant melanoma.
  • To highlight emerging strategies targeting NRAS and its downstream pathways.

Main Methods:

  • Review of preclinical studies on NRAS-mutant melanoma.
  • Analysis of current therapeutic strategies and clinical trial data.

Main Results:

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: May 23, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

  • NRAS mutations are associated with more aggressive melanoma phenotypes.
  • Therapeutic strategies targeting NRAS, including membrane localization inhibition and small interfering RNA (siRNA) approaches, are under investigation.
  • Clinical trials are evaluating downstream signaling inhibitors (MAPKK, PI3K/AKT).

Conclusions:

  • NRAS-mutant melanoma presents a significant therapeutic challenge.
  • Targeting NRAS directly or its downstream pathways holds potential for effective treatment.
  • Successful clinical application hinges on safe and effective delivery of combination therapies.